



BETA DRUGS LIMITED

18th October, 2018

The Manager
National Stock Exchange of India Ltd.
Exchange Plaza, C/1, Block G
Bandra - Kurla Complex, Bandra (East)
Mumbai 400 051

NSE Symbol: BETA

Sub: Intimation of Incorporation of Subsidiary Company in Republic of Uzbekistan.

With reference to the captioned subject, we would like to inform you that Beta Drugs Limited has entered into a joint venture with SILUJIN Private Co. Ltd, Uzbekistan by incorporating a subsidiary company namely, "BETA UBK INTERNATIONAL PRIVATE LIMITED" in Republic of Uzbekistan registered with Department of Company Affairs, Tashkent Province, Uzbekistan on 07.09.2018 to manufacture Oncology drugs in Uzbekistan. Beta will hold 60% in the joint venture and will become the first Indian company to manufacture Oncology drugs in Uzbekistan which is the largest CIS (Commonwealth of Independent States) nation. The subsidiary company has entered into a lease agreement on 17.10.2018 with DONATA PHARMA LLC, located in Tashkent Province to take on lease its facilities i.e. land, plant and machinery which confirm to European quality standards. The trial batches are likely to start in December, 2018 and the commercial production will start by March, 2019 and would be eligible to export to other CIS countries from Uzbekistan. This will impact Beta's topline and bottom line positively going forward.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD4/2015 dated 9th September, 2015 is given as under:

Sr. No.	Particulars	Details
(a)	Name of the target entity, details in brief such as size, turnover etc.	Beta Ubk International Private Limited is a newly incorporated subsidiary in which Beta Drugs Limited has 60% share and SILUJIN Private Co. Ltd, Uzbekistan has 40% share. Authorised Share Capital- \$ 80,000/- In which Beta Drugs Limited will contribute \$48000/- and Silujin Private Co. Ltd will contribute \$32000/- Turnover - Nil (Yet to commence Business operation)
(b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	Beta Ubk International Private Limited is a newly incorporated subsidiary in Uzbekistan in which Beta Drugs Limited has 60% share and SILUJIN Private Co. Ltd, Uzbekistan has 40% share. There is no acquisition. CIN No.: U24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com



(c)	Industry to which the entity being acquired belongs	Pharmaceutical.
(d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Manufacturing of Oncology Products.
(e)	Brief details of any governmental or regulatory approvals required for the acquisition.	No
(f)	Indicative time period for completion of the acquisition	N.A.
(g)	Nature of consideration – whether cash consideration or share swap and details of the same;	Cash
(h)	Cost of acquisition or the price at which the shares are acquired;	Beta Drugs Limited- \$48000/- Silujin Private Co. Ltd-\$32000/-
(i)	Percentage of shareholding / control acquired and / or number of shares acquired;	Beta Drugs Limited- 60% Silujin Private Co. Ltd-40%
(j)	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	“Beta Ubk International Private Limited” is a newly incorporated subsidiary in Uzbekistan registered with Department of Company Affairs, Tashkent Province, Uzbekistan in which Beta Drugs Limited has 60% share and SILUJIN Private Co. Ltd, Uzbekistan has 40% share and the subsidiary company is yet to commence its business operations.

Kindly take this on record.

Thanking you.

Yours faithfully,

For Beta Drugs Limited

Rajni
Rajni Brar
Company Secretary

